The annual incidence of malignant melanoma is estimated at 10–12 per 100 000 inhabitants in countries of Central Europe and the US, with more recent estimates showing a dramatic upward trend. Taurolidine (Carter/Wallace, Cranberry, NJ) is a novel, potentially effective, antitumor chemotherapeutic agent. We hypothesized that Taurolidine could inhibit the growth, induce apoptosis, affect the cell cycle and change morphology of melanoma cells. We expected this process to be different in adherent and floating subpopulations that may be reflective of solid tumors and their metastases. Analysis of MNT-1 human and B16F10 murine melanoma cells showed that at 72 h the IC50of Taurolidine was 25.4±3.3 μM for MNT-1 human melanoma cells and 30.9±3.6 μM for B16F10 murine melanoma cells. Taurolidine induced DNA fragmentation of melanoma cells in a dose-dependent manner. Taurolidine (75 and 100 μM) induced 52–97% Annexin-V binding (apoptosis), respectively. Evaluation of cell cycle after 72 h exposure to Taurolidine (0–100 μM) revealed that the percentage of melanoma cells in S phase increased from 27 to 40% in the adherent subpopulation and from 33 to 49% in the floating subpopulation. Phase contrast microscopy revealed a marked swelling of melanoma cells and decreasing cell numbers in adherent subpopulation starting at 24 h with 25 μM Taurolidine. Shrinkage of cells dominated at 75–100 μM Taurolidine. Using Cytospin assay in the floating population, we observed swelling of melanoma cells induced by 25–100 μM Taurolidine and appearance of giant (multinuclear) forms resulting from exposure to 75–100 μM Taurolidine. Some floating cells with normal morphology were observed with low concentrations of Taurolidine (0–25 μM). These data show that effects of Taurolidine may be different in adherent and floating subpopulations of melanoma cells. More importantly, floating subpopulations that may contain some viable melanoma cells, may be reflective of potential metastasis after treatment of solid tumorsin vivo.